PL3010506T3 - Pridopidyna w leczeniu choroby huntingtona - Google Patents

Pridopidyna w leczeniu choroby huntingtona

Info

Publication number
PL3010506T3
PL3010506T3 PL14813621T PL14813621T PL3010506T3 PL 3010506 T3 PL3010506 T3 PL 3010506T3 PL 14813621 T PL14813621 T PL 14813621T PL 14813621 T PL14813621 T PL 14813621T PL 3010506 T3 PL3010506 T3 PL 3010506T3
Authority
PL
Poland
Prior art keywords
pridopidine
disease
treating huntington
huntington
treating
Prior art date
Application number
PL14813621T
Other languages
English (en)
Polish (pl)
Inventor
Merav Bassan
Eli Eyal
Esther Lukasiewicz Hagai
Anna Kristina Sveinsdotter Teige Wickenberg
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3010506(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3010506T3 publication Critical patent/PL3010506T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14813621T 2013-06-21 2014-06-19 Pridopidyna w leczeniu choroby huntingtona PL3010506T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease
EP14813621.1A EP3010506B1 (en) 2013-06-21 2014-06-19 Pridopidine in treating huntington's disease

Publications (1)

Publication Number Publication Date
PL3010506T3 true PL3010506T3 (pl) 2021-11-02

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14813621T PL3010506T3 (pl) 2013-06-21 2014-06-19 Pridopidyna w leczeniu choroby huntingtona

Country Status (24)

Country Link
US (1) US10322119B2 (enExample)
EP (1) EP3010506B1 (enExample)
JP (1) JP2016523862A (enExample)
KR (1) KR102316933B1 (enExample)
CN (1) CN105592848A (enExample)
AU (1) AU2014281414A1 (enExample)
BR (1) BR112015029918A2 (enExample)
CA (1) CA2913781C (enExample)
CL (1) CL2015003690A1 (enExample)
DK (1) DK3010506T3 (enExample)
EA (1) EA201690069A1 (enExample)
ES (1) ES2879631T3 (enExample)
HK (1) HK1221646A1 (enExample)
HU (1) HUE054783T2 (enExample)
IL (1) IL242804B (enExample)
MX (1) MX384234B (enExample)
PE (2) PE20160195A1 (enExample)
PH (1) PH12015502691A1 (enExample)
PL (1) PL3010506T3 (enExample)
SG (1) SG11201509729YA (enExample)
TW (1) TW201529069A (enExample)
UA (1) UA122999C2 (enExample)
UY (1) UY35624A (enExample)
WO (1) WO2014205229A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PH12013500406A1 (en) 2010-09-03 2019-07-17 Teva Pharmaceuticals Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN106170287A (zh) * 2014-01-22 2016-11-30 梯瓦制药国际有限责任公司 改进释放的普利多匹定制剂
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) * 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
PL3419622T3 (pl) 2016-02-24 2024-07-08 Prilenia Neurotherapeutics Ltd. Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny
WO2018039477A1 (en) * 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
JP7278210B2 (ja) * 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
US20200375966A1 (en) * 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
DK4005570T3 (da) 2016-09-16 2024-08-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse behandling af retts syndroe
AU2018210145B2 (en) 2017-01-20 2023-06-29 Agency For Science, Technology And Research Use of pridopidine for the treatment of fragile X syndrome
EP3668509B1 (en) * 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
BR112020004622A2 (pt) 2017-09-08 2020-09-24 Prilenia Neurotherapeutics Ltd. pridopidina para tratamento de discinesias induzidas por droga
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN113365551A (zh) * 2019-01-31 2021-09-07 豪夫迈·罗氏有限公司 评估亨廷顿氏病的进展
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
JP7436524B2 (ja) * 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
JP4891908B2 (ja) 2004-10-13 2012-03-07 エヌエスエービー，フィリアル アフ ニューロサーチ スウェーデン アクチボラゲット，スヴェリエ ４−（３−メタンスルホニルフェニル）−１−ｎ−プロピルピペリジンの合成方法
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
EP2146961B1 (en) 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
PH12013500406A1 (en) 2010-09-03 2019-07-17 Teva Pharmaceuticals Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) * 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
US9012476B2 (en) * 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
EP2900330A4 (en) 2012-09-27 2016-05-25 Teva Pharma LAQUINIMOD AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20150216850A1 (en) 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
CN106170287A (zh) 2014-01-22 2016-11-30 梯瓦制药国际有限责任公司 改进释放的普利多匹定制剂
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
DK4005570T3 (da) 2016-09-16 2024-08-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse behandling af retts syndroe
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia

Also Published As

Publication number Publication date
UA122999C2 (uk) 2021-02-03
HUE054783T2 (hu) 2021-09-28
JP2016523862A (ja) 2016-08-12
US20140378508A1 (en) 2014-12-25
EP3010506A1 (en) 2016-04-27
WO2014205229A8 (en) 2015-04-09
EA201690069A1 (ru) 2016-06-30
UY35624A (es) 2015-01-30
AU2014281414A1 (en) 2016-01-21
SG11201509729YA (en) 2015-12-30
CL2015003690A1 (es) 2016-10-28
DK3010506T3 (da) 2021-07-12
EP3010506B1 (en) 2021-05-12
ES2879631T3 (es) 2021-11-22
WO2014205229A1 (en) 2014-12-24
MX2015017307A (es) 2016-08-03
IL242804B (en) 2022-02-01
CN105592848A (zh) 2016-05-18
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
US10322119B2 (en) 2019-06-18
PE20170302A1 (es) 2017-03-31
PE20160195A1 (es) 2016-05-14
HK1221646A1 (zh) 2017-06-09
CA2913781C (en) 2022-05-10
TW201529069A (zh) 2015-08-01
EP3010506A4 (en) 2017-02-08
KR20160055122A (ko) 2016-05-17
CA2913781A1 (en) 2014-12-24
KR102316933B1 (ko) 2021-10-26
BR112015029918A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
PL3010506T3 (pl) Pridopidyna w leczeniu choroby huntingtona
EP3068905A4 (en) Methods and compositions for treating huntington's disease
ZA201406209B (en) Methods and compositions for treating huntington's disease
HUE068364T2 (hu) Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
GB201310203D0 (en) Materials and methods relating to Alzheimer's disease
EP2980096A4 (en) 2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof
GB201214450D0 (en) Huntington's disease
AU353890S (en) Men's clothing
ZA201407032B (en) Preventing or treating periodontal disease
GB201309694D0 (en) Artist's implement
GB201310607D0 (en) B'jamas
AU350798S (en) Alu' sling sunlounger
GB201301407D0 (en) 17 Deemed-Ties Blackjack
GB201309270D0 (en) Line-out Rugby aid 'Get Up's'
GB201322568D0 (en) Taggstar 1
BR302013005287S1 (pt) Configuração introduzida em calçado feminino
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270
GB201304148D0 (en) Improvements in or relating to treatment apparatus
GB201311489D0 (en) Concept 52
GB201311503D0 (en) Concept 38
GB201311522D0 (en) Concept 40
GB201311519D0 (en) Concept 39